NeurologyOnline.net

Neurology Xagena

A study has evaluated the efficacy and safety of subcutaneous Peginterferon beta-1a ( Plegridy ) over 2 years in patients with relapsing-remitting multiple sclerosis in the ADVANCE study. Patients ...


Up to 70% of Parkinson’s disease ( PD ) patients experience sleep problems that negatively impact their quality of life. Some patients have disturbed sleep/wake patterns such as difficulty falling asl ...


Deep brain stimulation ( DBS ) has become a well-recognized nonpharmacologic treatment that improves motor symptoms of patients with early and advanced Parkinson’s disease. Evidence now indicates th ...


The FDA ( Food and Drug Administration ) has approved Lemtrada ( Alemtuzumab ) for the treatment of patients with relapsing forms of multiple sclerosis ( MS ). Because of its safety profile, the use o ...


It is known that the risk of stroke in patients with traumatic brain injury might be increased. However, the relationship between mild traumatic brain injury and ischemic stroke has never been establi ...


Phase IIa clinical trial data on ATL1102 were published in the medical journal Neurology. The article highlights the successful outcomes of the randomised, double-blind, placebo-controlled study in 77 ...


The evaluation of therapeutic choices is needed after 24 doses of Natalizumab ( Tysabri ) in patients with multiple sclerosis ( MS ). A study has evaluated the effect of therapeutic choices on the me ...


No reliable treatment options are known for progressive multifocal leukoencephalopathy with underlying immunodeficiency. Researchers have described successful compassionate use of in a patient with ...


Five-year results from the ENDORSE phase 3 extension study have shown Dimethyl fumarate ( Tecfidera ) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting ...


In a 6-month double-blind, placebo-controlled study of Parkinson's disease patients with motor fluctuations, Safinamide 50 and 100 mg/d significantly increased ON-time without increasing dyskinesia. ...


Many of those who are genetically predisposed to develop atrial fibrillation, which dramatically raises the risk of stroke, can be identified with a blood test. This is shown by new research from Lund ...


Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented at the European Committee for Research and Treatment in Multiple Sclerosis ...


A follow-up study of patients with Parkinson’s disease ( PD ) who participated in an earlier proof of concept clinical trial using Exenatide showed that improvements persisted twelve months after disc ...


The full results from the phase 3 DECIDE clinical trial have shown a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis ( RRMS ) w ...


The phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis ( RMS ) met the primary endpoint, reduction in MRI brain lesion activity. ...


The prognostic significance of age and continuous positive airway pressure ( CPAP ) therapy on cardiovascular disease in patients with sleep apnoea has not been assessed previously. Using nationwid ...


It is studied the applicability of the Acute Physiology and Chronic Health Evaluation II ( APACHE II ) and Simplified Acute Physiology Score II ( SAPS II ) in patients admitted to the intensive care u ...


The FDA-approved trial, A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Scler ...


A study has evaluated the ability of Lithium carbonate and Valproate cotreatment to modify the survival rate and functional score of patients with definite sporadic amyotrophic lateral sclerosis ( ALS ...


In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received Daclizumab high-yield process ( HYP ) for 52 weeks. The primary aim of the SELECTION extension st ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati